Multiple myeloma: open trials in Hungary

• NCT07589634

  A Study Evaluating the Prophylactic Use of Tocilizumab to Prevent Cytokine Release Syndrome With Ramantamig Administration in Participants With Relapsed/Refractory Multiple Myeloma

  Trial Treatment · Phase 2 · Janssen Research & Development, LLC

  Semmelweis Egyetem, Budapest · Del Pesti Centrumkorhaz Orszagos Hematologiai es Infektologiai Intezet Szent Laszlo Telephely, Budapest · Orszagos Onkologiai Intezet, Budapest · Pécsi Tudományegyetem Klinikai Központ, Pécs · Szegedi Tudomanyegyetem Altalanos Orvostudomanyi Kar, Szeged

  Registry updated 2026-11-03

• NCT06615479

  A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

  Trial Treatment · Phase 3 · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

  Del-Pesti Centrumkorhaz Orszagos Hematologiai Es Infektologiai Intezet, Budapest IX · University of Debrecen, Debrecen

  Registry updated 2026-10-29

• NCT06980480

  A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma

  Trial Treatment · Phase 3 · Takeda

  Semmelweis University, Budapest VIII · University of Debrecen, Debrecen · Somogy Vármegyei Kaposi Mór Oktató Kórház, Kaposvár · Vas Varmegyei Markusovszky Egyetemi Oktatokorhaz, Szombathely

  Registry updated 2026-10-13

• NCT05645107

  A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma

  Trial Treatment · Phase 3 · Grifols Therapeutics LLC

  Del-Pesti Centrumkorhaz Orszagos Hematologiai Es Infektologiai Intezet, Budapest IX · Orszagos Onkologiai Intezet, Budapest XII · University of Debrecen, Debrecen · Markhot Ferenc Oktatokorhaz es Rendelointezet, Eger · Petz Aladar Egyetemi Oktato Korhaz, Győr · University of Szeged, Szeged · Fejér Megyei Szent György Egyetemi Oktató Kórház, Székesfehérvár · Tolna Megyei Balassa Janos Korhaz, Szekszárd

  Registry updated 2026-09-30

• NCT04879043

  Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

  Trial Treatment · Phase 1/2 · Heidelberg Pharma AG

  Semmelweis University, Budapest VIII · Orszagos Onkologiai Intezet, Budapest XII · University of Pecs, Pécs

  Registry updated 2026-09-17

• 2025-524793-42-00

  Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma

  Trial Treatment · Phase 2 · Janssen Cilag International

  Del-Pesti Centrumkorhaz Orszagos Hematologiai Es Infektologiai Intezet, Budapest IX · Semmelweis University, Budapest VIII · Orszagos Onkologiai Intezet, Budapest XII · University of Debrecen, Debrecen · University of Pecs, Pécs · University of Szeged, Szeged

  Registry updated 2026-09-11

• NCT07728188

  A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma

  Trial Treatment · Phase 3 · AbbVie

  Vas Varmegyei Markusovszky Egyetemi Oktatokorhaz /ID# 283136, Szombathely

  Registry updated 2026-07-27

All Multiple myeloma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error